aMoon Fund

aMoon is a global HealthTech and Life Sciences investment fund based in Israel, partnering with entrepreneurs to transform healthcare.

Venture Capital Active Ra'anana, Israel Est. 2016
Visit website ↗ LinkedIn
Last updated 2026-07-20
Portfolio
8
in our dataset
Rounds participated
8
Rounds led
0
Rounds' value
$122.0M
total disclosed, rounds participated
Stages
E Round, Pre-Seed, D Round, Seed, B Round, C Round, F Round, G Round, A Round

About

aMoon Fund is a leading venture capital firm based in Ra'anana, Israel, specializing in life sciences and health technology ventures. Founded in 2016 by Dr. Yair Schindel and Marius Nacht, aMoon focuses on transforming healthcare by investing in innovative companies that leverage groundbreaking science and technology. The firm manages over $1.3 billion in assets and operates multiple funds, including aMoon Velocity (early-stage) and aMoon Growth (later-stage), with a global investment focus that includes Israel, the United States, Europe, and Asia. aMoon aims to accelerate the development of solutions that address high unmet medical needs, positioning itself as a key player in the HealthTech sector. They invest across various stages, from pre-seed to growth equity, in areas such as biopharma, digital health, and medical technology.

Portfolio · 8

MDSG Innovation
Medical Technology Innovation Platform
1 round Latest: 2021-01
Vocalis Health
Voice-based Analysis and Detection of Different Health Conditions
1 round $9.0M committed Latest: 2019-12
DayTwo
Precision Nutrition for Metabolic Disease
1 round $31.0M committed Latest: 2019-06
TaGeza Biopharmaceuticals
Antibodies to Cancer Stem Cell Receptors
1 round Latest: 2019-01
CTG Pharma
Enabling Therapeutic Application of Chimeric Antigen Receptor T Cells in Solid Tumors
1 round $2.0M committed Latest: 2018-09
Medial EarlySign
Early Detection of Life-threatening Conditions
1 round $30.0M committed Latest: 2018-03
Regenera Pharma
Regenerative Therapy for Neuropathies
1 round $20.0M committed Latest: 2018-01
Pharma Two B
Innovative Combinations of Previously Approved Drugs
1 round $30.0M committed Latest: 2017-02

Investment activity

4 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences33
Industrial Technologies1
Retail Platforms1

Funds · 3

  • Growth II — $340M Jul 2022
  • Velocity — $114M Jan 2019
  • Growth I — $750M Jan 2018

Q&A

What is aMoon Fund's primary investment focus?
aMoon Fund is Israel’s largest HealthTech-only VC fund, focusing on companies that leverage groundbreaking science and technology to transform healthcare.
What is the total AUM for aMoon Fund?
aMoon Fund has over $1.3 billion in Assets Under Management (AUM).
Which notable exits has aMoon Fund had recently?
aMoon Fund had a notable exit in February 2026 with the acquisition of MetaSight Diagnostics by Guardant Health for $150 million. Another significant exit was CartiHeal, acquired by Bioventus in May 2022.
What is aMoon Fund's most recent fund close?
aMoon Fund closed its Growth II fund in July 2022, raising $340 million.
Can you name some of aMoon Fund's portfolio companies?
aMoon Fund's portfolio includes companies like Ultima Genomics, which raised $604.22 million in a Seed round, and Eleos Health, which raised $128 million in a Series C round.
What investment stages does aMoon Fund typically participate in?
aMoon Fund invests across all stages of a company’s lifecycle, including Pre-Seed, Seed, A, B, C, D, E, F, and G Rounds.
Who is a co-founder and managing partner at aMoon Fund?
Yair Schindel, MD, MBA, is a Co-Founder and Managing Partner at aMoon Fund.
What was the size of aMoon Fund's Growth I fund?
aMoon Fund's Growth I fund, closed in January 2018, raised $750 million.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)